Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra

Executive Summary

Ixifi (infliximab-qbtx), which references Janssen's Remicade, marks first US approval of a biosimilar developed entirely by Pfizer; big pharma says it is not currently planning to launch Ixifi because it remains "committed" to marketing Celltrion's Inflectra.


Related Content

10 Things For Pfizer's New CEO To Worry About
EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic
EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic
Biosimilar Legal Landscape: Lessons From 2017
Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts
Pfizer Will Support Inflectra Launch With Dedicated Sales Force
Sandoz Picks Up Pfizer's Infliximab Biosimilar
Pfizer/Hospira's Biosimilar Pipeline: Substantial Overlap, Limited Divestiture So Far
EU Demands Pfizer Offload Infliximab Biosimilar In Hospira Buy
Where's the value in Pfizer's $17bn Hospira buy?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts